INFLIXIMAB-DYYB
Manufacturer: Pfizer Laboratories Div Pfizer Inc
Score: 144.0
INFLECTRA (INFLIXIMAB-DYYB) is a tumor necrosis factor (TNF) blocker indicated for the treatment of various conditions, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It works by neutralizing the biological activity of TNFα, a substance in the body that causes inflammation and is involved in autoimmune diseases. The recommended dosage of INFLECTRA varies depending on the condition being treated, with typical dosing regimens including an initial induction regimen followed by maintenance dosing. Important safety information includes an increased risk of serious infections, malignancies, and other adverse reactions, as well as contraindications for patients with certain medical conditions or taking certain medications. Special population considerations include use during pregnancy, nursing mothers, pediatric use, and geriatric use.
SERIOUS INFECTIONS and MALIGNANCY
Dose adjustments may be necessary for patients with certain medical conditions or taking certain medications
5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks
5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks for patients 6 years and older
5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks
5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks for patients 6 years and older
3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks
Not established
5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks
Not established
5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks
Not established
5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks
Not established